Patient Types/Special Populations: Suppressed Switch

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

Cabotegravir

The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

Cabotegravir

X
Dovato Real World Evidence Video

Dovato Real World Evidence Video

Dr. Benjamin Young, Head of Global Medical Directors

Dolutegravir Based Regimens

Dovato Real World Evidence Video

Dr. Benjamin Young, Head of Global Medical Directors

Dolutegravir Based Regimens

X
DTG+3TC: TANGO 96-Week Data

DTG+3TC: TANGO 96-Week Data

An Update from HIV GLASGOW 2020

Jose Gatell, Senior Global Medical Director

Dolutegravir Based Regimens

DTG+3TC: TANGO 96-Week Data

An Update from HIV GLASGOW 2020

Jose Gatell, Senior Global Medical Director

Dolutegravir Based Regimens

X
DTG: Metabolic Data Update

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Mark Underwood, Clinical Virologist and Development Investigator

Dolutegravir Based Regimens

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Mark Underwood, Clinical Virologist and Development Investigator

Dolutegravir Based Regimens

X
TANGO Study: Metabolic Substudy

TANGO Study: Metabolic Substudy

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

TANGO Study: Metabolic Substudy

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
Antiretroviral Therapy and Weight Gain

Antiretroviral Therapy and Weight Gain

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

Antiretroviral Therapy and Weight Gain

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
DTG/3TC: Barrier to Resistance

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

Dolutegravir Based Regimens

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

Dolutegravir Based Regimens

X
DTG/3TC: Real-World Evidence

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X
TANGO 96 Week: Efficacy and Safety

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dolutegravir Based Regimens

X

Are you a US healthcare provider?

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.

Connect with our Medical Experts

Find my ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1-888-226-8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch